534 related articles for article (PubMed ID: 30424732)
1. Biaryl scaffold-focused virtual screening for anti-aggregatory and neuroprotective effects in Alzheimer's disease.
Khalid S; Zahid MA; Ali H; Kim YS; Khan S
BMC Neurosci; 2018 Nov; 19(1):74. PubMed ID: 30424732
[TBL] [Abstract][Full Text] [Related]
2. In silico repurposing of antipsychotic drugs for Alzheimer's disease.
Kumar S; Chowdhury S; Kumar S
BMC Neurosci; 2017 Oct; 18(1):76. PubMed ID: 29078760
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective effects of bergenin in Alzheimer's disease: Investigation through molecular docking, in vitro and in vivo studies.
Barai P; Raval N; Acharya S; Borisa A; Bhatt H; Acharya N
Behav Brain Res; 2019 Jan; 356():18-40. PubMed ID: 30118774
[TBL] [Abstract][Full Text] [Related]
4. Sarsasapogenin: A steroidal saponin from Asparagus racemosus as multi target directed ligand in Alzheimer's disease.
Kashyap P; Muthusamy K; Niranjan M; Trikha S; Kumar S
Steroids; 2020 Jan; 153():108529. PubMed ID: 31672628
[TBL] [Abstract][Full Text] [Related]
5. New neurogenic lipoic-based hybrids as innovative Alzheimer's drugs with σ-1 agonism and β-secretase inhibition.
Estrada M; Pérez C; Soriano E; Laurini E; Romano M; Pricl S; Morales-García JA; Pérez-Castillo A; Rodríguez-Franco MI
Future Med Chem; 2016 Jul; 8(11):1191-207. PubMed ID: 27402296
[TBL] [Abstract][Full Text] [Related]
6. Molecular docking and molecular dynamics approach to identify potential compounds in
Tung BT; Hang TTT; Kim NB; Nhung NH; Linh VK; Thu DK
J Complement Integr Med; 2022 Dec; 19(4):955-965. PubMed ID: 35621378
[TBL] [Abstract][Full Text] [Related]
7. Novel small molecule therapeutic agents for Alzheimer disease: Focusing on BACE1 and multi-target directed ligands.
Iraji A; Khoshneviszadeh M; Firuzi O; Khoshneviszadeh M; Edraki N
Bioorg Chem; 2020 Apr; 97():103649. PubMed ID: 32101780
[TBL] [Abstract][Full Text] [Related]
8. Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with γ-secretase and regulates neuronal amyloid β-peptide levels.
Schedin-Weiss S; Inoue M; Hromadkova L; Teranishi Y; Yamamoto NG; Wiehager B; Bogdanovic N; Winblad B; Sandebring-Matton A; Frykman S; Tjernberg LO
Alzheimers Res Ther; 2017 Aug; 9(1):57. PubMed ID: 28764767
[TBL] [Abstract][Full Text] [Related]
9. BACE1 molecular docking and anti-Alzheimer's disease activities of ginsenosides.
Choi RJ; Roy A; Jung HJ; Ali MY; Min BS; Park CH; Yokozawa T; Fan TP; Choi JS; Jung HA
J Ethnopharmacol; 2016 Aug; 190():219-30. PubMed ID: 27275774
[TBL] [Abstract][Full Text] [Related]
10. Uleine Disrupts Key Enzymatic and Non-Enzymatic Biomarkers that Leads to Alzheimer's Disease.
Seidl C; de Moraes Santos CA; De Simone A; Bartolini M; Weffort-Santos AM; Andrisano V
Curr Alzheimer Res; 2017; 14(3):317-326. PubMed ID: 27784218
[TBL] [Abstract][Full Text] [Related]
11. Flavanone glycosides inhibit β-site amyloid precursor protein cleaving enzyme 1 and cholinesterase and reduce Aβ aggregation in the amyloidogenic pathway.
Ali MY; Jannat S; Edraki N; Das S; Chang WK; Kim HC; Park SK; Chang MS
Chem Biol Interact; 2019 Aug; 309():108707. PubMed ID: 31194956
[TBL] [Abstract][Full Text] [Related]
12. Identifying natural compounds as multi-target-directed ligands against Alzheimer's disease: an in silico approach.
Ambure P; Bhat J; Puzyn T; Roy K
J Biomol Struct Dyn; 2019 Mar; 37(5):1282-1306. PubMed ID: 29578387
[TBL] [Abstract][Full Text] [Related]
13. New flavonoid -
Estrada-Valencia M; Herrera-Arozamena C; Pérez C; Viña D; Morales-García JA; Pérez-Castillo A; Ramos E; Romero A; Laurini E; Pricl S; Rodríguez-Franco MI
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):712-727. PubMed ID: 31852270
[TBL] [Abstract][Full Text] [Related]
14.
Ayaz M; Wadood A; Sadiq A; Ullah F; Anichkina O; Ghufran M
J Biomol Struct Dyn; 2022; 40(20):10230-10238. PubMed ID: 34157942
[TBL] [Abstract][Full Text] [Related]
15. Dual-target compounds for Alzheimer's disease: Natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR).
Ferreira JPS; Albuquerque HMT; Cardoso SM; Silva AMS; Silva VLM
Eur J Med Chem; 2021 Oct; 221():113492. PubMed ID: 33984802
[TBL] [Abstract][Full Text] [Related]
16. Recent Studies on Design and Development of Drugs Against Alzheimer's Disease (AD) Based on Inhibition of BACE-1 and Other AD-causative Agents.
Gupta SP; Patil VM
Curr Top Med Chem; 2020; 20(13):1195-1213. PubMed ID: 32297584
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel multifunctional ligands targeting GABA transporters, butyrylcholinesterase, β-secretase, and amyloid β aggregation as potential treatment of Alzheimer's disease.
Zaręba P; Łątka K; Mazur G; Gryzło B; Pasieka A; Godyń J; Panek D; Skrzypczak-Wiercioch A; Höfner GC; Latacz G; Maj M; Espargaró A; Sabaté R; Jóźwiak K; Wanner KT; Sałat K; Malawska B; Kulig K; Bajda M
Eur J Med Chem; 2023 Dec; 261():115832. PubMed ID: 37837674
[TBL] [Abstract][Full Text] [Related]
18. A review on flavonoid-based scaffolds as multi-target-directed ligands (MTDLs) for Alzheimer's disease.
Jalili-Baleh L; Babaei E; Abdpour S; Nasir Abbas Bukhari S; Foroumadi A; Ramazani A; Sharifzadeh M; Abdollahi M; Khoobi M
Eur J Med Chem; 2018 May; 152():570-589. PubMed ID: 29763806
[TBL] [Abstract][Full Text] [Related]
19. Multifunctional iminochromene-2H-carboxamide derivatives containing different aminomethylene triazole with BACE1 inhibitory, neuroprotective and metal chelating properties targeting Alzheimer's disease.
Iraji A; Firuzi O; Khoshneviszadeh M; Tavakkoli M; Mahdavi M; Nadri H; Edraki N; Miri R
Eur J Med Chem; 2017 Dec; 141():690-702. PubMed ID: 29107423
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory activities of major anthraquinones and other constituents from Cassia obtusifolia against β-secretase and cholinesterases.
Jung HA; Ali MY; Jung HJ; Jeong HO; Chung HY; Choi JS
J Ethnopharmacol; 2016 Sep; 191():152-160. PubMed ID: 27321278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
